Abnormal hematological indices in cirrhosis

Canadian Journal of Gastroenterology

Volumn 23, Issue 6, 2009, Pages 441-445

  Qamar, Amir A ^a   Grace, Norman D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anemia; Cirrhosis; Hyperplenism; Leukopenia; Thrombocytopenia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ELTROMBOPAG; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; PLACEBO; PROPRANOLOL; PROTON PUMP INHIBITOR; RIBAVIRIN; THROMBOPOIETIN;

ABNORMAL LABORATORY RESULT; ANEMIA; BLOOD TRANSFUSION; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HORMONE SYNTHESIS; HUMAN; HYPERSPLENISM; LEUKOCYTE COUNT; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PANCYTOPENIA; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

EID: 69949109982     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/591317     Document Type: Review

References (56)

1. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001;13:317-23.
2. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000:13 (Suppl D):60D-6D.
3. Toghill PJ, Green S, Ferguson F. Platelet dynamics in chronic liver disease with special reference to the role of the spleen. J Clin Pathol 1977;30:367-71.
4. Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of hypersplenic thrombocytopenia. J Clin Invest 1966;415:645-57.
5. Subiyah BW, Al-Hindawi A. Red cell survival and splenic accumulation of radiochromuim in liver cirrhosis with splenomegaly. Br J Haematol 1967;13:773-8.
6. Blackman A, Grace N, Chandler H, et al. Hypersplenism in cirrhosis: Measurements of portal pressure, spleen size and circulating blood cell disappearance rates. Clin Res 1969;17:A298.
7. Qamar AA, Grace ND. Groszmann RJ, et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008;47:153-9.
8. Qamar AA, Grace ND, Groszmann RJ, et al. The incidence, prevalence and clinical significance of abnormal hematological indices in patients with compensated cirrhosis. Clin Gastroenterol Hepatol 2009, In press.
9. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997;27:127-31.
10. Martin TG III, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285-8.
11. Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754-8.
12. Stiegler G, Stohlawetz P, Peck-Radosavljevic M, et al. Direct evidence for an increase in thrombopoiesis after liver transplantation. Eur J Clin Invest 1998;28:755-9.
13. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-22.
14. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrumbopoietin induces rapid resolution of thrombocytopenia after ordiotopic liver transplantation through increased platelet production. Blood 2000;95:795-801.
15. Peck-Radosavljevic M, Zacherl J, Wichlas M, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gastroenterol Hepatol 1999;11:151-6.
16. Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003;98:2516-20.
17. Rios R, Sangro B, Herrero I, et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005;100:1311-6.
18. Sezai S, Kamisaka K, Ikegami F, et al. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenoterol 1998;93:80-2.
19. Yang YY, Lin HC, Lee WC, et al. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol 2003;18:1156-61.
20. Bruno CM, Neri S, Sciacca C, et al. Plasma erythropoietin levels in anaemic and non-anaemic. patients with chronic liver diseases. World J Gastroenterol 2004;10:1353-6.
21. Gurakar A, Fagiuoli S, Gavaler JS, et al. The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. J Hepatol 1994;21:582-6.
22. Morlock CG, Hall BE. Association of cirrhosis, thrombocytopenia and hemorrhagic tendency. Arch Intern Med 1943;72:69-77.
23. Mutchnik MG, Lerner E, Conn HO. Effect of portocaval anastamosis on hypersplenism. Dig Dis Sci 1980;25:929-38.
24. Sullivan BH, Tumen HJ. The effect of portocaval shunt on thrombocytopenia associated with portal hypertension. Ann Intern Med 1961;55:598-603.
25. Soper NJ, Nikker LF. Effect of operations for variceal hemorrhage on hypersplenism. Am J Surg 1982; 144:700-3.
26. Hutson DG, Zeppa R, Levi J, et al. The effect of distal splenorenal shunt on hypersplenism. Ann Surg 1977;185:605-12.
27. Ferrara J, Ellison C, Martin EW, et al. Correction of hypersplenism following DSRS. Surgery 1979;86:570-3.
28. Pusnani K, Sillin L, Kaplan D, et al. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 1997;173:169-73.
29. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J.Gastroenterol 2000;95:2936-9.
30. Liangpunsakul S, Sithat M, Ulmer B, et al. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sciences 2003;326:111-16.
31. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary, sclerosing cholangitis Hepatology 2004;39:204-10.
32. Pilette C, Oberti F, Aube C, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol 1999;31:867-73.
33. Zaman A, Hapke R, Flora K, Rosen, HR, Benner K. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999;94:3292-6.
34. Madhotra R, Mulcahy HE, Willnet I, Reuben A. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol 2002;34:81-5.
35. Sanyal AJ, Fontana RJ, Di Bisceglie AM, et al; and the HALT-C Trial Group. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006;64:855-64.
36. Felix WR, Myerson RM, Sigel B, et al. The effect of portocaval shunt on hypersplenism. Surg Gyn Obs 1974;139:899-904.
37. Jackson FC, Perrin EB, Smith AG, et al. A clinical investigation of the portocaval shunt-II: Survival analysis ofthe prophylactic operation. Am J Surg 1968;115:22-42.
38. Rousselot LM, Pantre WF. Bono RF, et al. Experiences with portocaval anastamosis: Analysis of 104 elective end to side shunts for the prevention of recurrent hemorrhage from esophagogastric varices (1952-1961). Am J Med 1963;34:297-307.
39. Morris PW, Patton TB, Balint JA, et al. Portal hypertension, congestive splenomegaly and portocaval shunt. Gastroenterol 1962;42:555-9.
40. Puttini M, Marni A, Montes F, et al. The effect of portasystemic shunt on hypersplenism: Clinical study in 129 patients with cirrhosis. Am J Surg 1979;45:444-8.
41. McAllister E, Goode S, Cordista AG, et al. Partial portal decompression alleviates thrombocytopenia of portal hypertension. Am J Surg 1995;61:129-31.
42. Mutchnick MG. Lerner E, Conn HO. Effect of portocaval anastamosis on hypersplenism. Dig Dis Sci 1980;25:929-38.
43. Macpherson AI, Innes J. Peripheral blood picture after operation for portal hypertension. Lancet 1953;264:1120-3.
44. Vang J, Simert G, Hansson JA, et al. Results of a modified distal spleno-renal shunt for portal hypertension. Ann Surg 1977;185:224-8.
45. Gschwantler M, Vavrik J, Gebauer A, et al. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt - a prospective, controlled study. J Hepatol 1999;30:254-9.
46. Kishore G, Pursnani MD, Sillin LF, et al. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 1997;173:169-73.
47. Jalan R, Redhead DN, Allan PL, et al. Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 1996;8:381-5.
48. Lawrence SP, Lezotte DC, Durham JD, at al. Course of thrombocytopenia of chronic liver disease after tramjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis. Dig Dis Sci 1995;40:1575-80.
49. Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996;23:32-9.
50. Karasu Z, Gurakar A, Kerwin B, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 2000;45:1971-1976.
51. Jabbour N, Zajko A, Orons P, et al. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998;43:2459-62.
52. Preneta E, Garcia-Tsao G, Grace ND, et al. Effect of propranolol therapy on platelet counts in cirrhotic patients with portal hypertension. Hepatology 1998;28,4 Pt 2:A1163 (Abstr).
53. Sekai K, Iwao T, Oho K, et al. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. J Gastroenterol 2002;37:112-8.
54. McHutchinson JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36.
55. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598-1606.
56. Spiegel BM, Chen K, Chiou CF, et al. Erythropoietic growth factors for treatment-indured anemia in hepatitis C: A cost-effectiveness analysis. Clin Gastroenterol 2005;3:1034-42.